At the end of the open-label phase 264 patients out of 349 (76%) reported adequate relief of their symptoms. These findings are consistent with previously published data from three studies of acute intestinal infection in children. 8–10 Diarrhoea resolved more rapidly in patients treated with Enterosgel compared with standard care 8 or antibiotic and standard care. 9 In a randomised prospective open comparative study of the intestinal adsorbents, Enterosgel, Diosmectite and Kaolin, there were no statistically significant differences between the groups for the duration of diarrhoea. Other studies have shown that Enterosgel use in newborns with rotavirus infection can reduce the duration of diarrhoea by 1.4 times, 11 and in antibiotic-associated diarrhoea in adults, result in a decrease in length of hospital stay. 12 The treatments recommended for acute diarrhoea by the National Institute for Health and Care Excellence guidance are fluid and nutritional management, with antidiarrhoeal (antimotility) drugs considered unnecessary and only advisable for specified groups.

Enterosgel 225g – IBS-D Treatment, Diarrhoea Relief

Enterosgel is a tasteless gel which when mixed with water forms a slightly opaque liquid, which people find tolerable and easy to drink. For children 15+ and adults: 15g to 22.5g (≈ 1 tablespoon or 1–1.5 sachet) diluted in 200 ml of water 3 times a day.No, Enterosgel is composed of organic mineral and doesn’t contain any ingredients of animal or plant origin. For this reason, Enterosgel does not need to be stored in the fridge but at a temperature of between 4-30°C and away from direct sunlight Randomised, multi-centre study to assess efficacy, tolerability and safety of Enterosgel® in treatment of acute diarrhoea in adults

IFU – Enterosgel | Official Website | Drug-Free IBS Diarrhoea

Enterosgel is an oral adsorbent, typical of several materials, such as charcoal, clay, silica-based materials and dietary fibres used to treat poisoning and different diseases, such as diarrhoea. 15 The therapeutic mode of action of Enterosgel may occur through the adsorption of bacterial toxins known causes of diarrhoea followed by complete removal from the body. In-vitro studies have demonstrated Enterosgel’s capacity for Escherichia coli endotoxin, bacterial enterotoxins Clostridium difficile toxin A and B, and Shigella toxin 16 and staphylococcal enterotoxins A and B. 17 Other mechanisms may include creation of an adverse environment for pathogenic microorganisms, 18 immunocorrection 19 and inhibiting viral replication, 20 primarily through physical adsorption. A possible benefit of Enterosgel use is in reducing the level of complications of diarrhoea-related bacterial infection. Prospective studies have shown that up to 36% of intestinal infections can be followed by prolonged post-infective irritable bowel syndrome. 21 Thus, treatment with Enterosgel could offer a reduction in secondary care admissions, and financial burden on the health service. However, a large-scale study is recommended with health economics evaluation before introducing Enterosgel onto the UK’s drug tariff.I've been suffering with IBS for the past 10 years and this actually works for me, helps relieve all symptoms and feel i can go out without having to worry. Following 8 weeks of open-label treatment, 349 patients completed the open-label phase. Comparison with secondary outcome data reported during the double-blind phase confirmed continued treatment effect for the same observed variables ( online supplemental files S7–S10). Mean days per week loperamide use fell in the Enterosgel group in contrast to the placebo (week 1: 0.83 vs 1.14, week 8: 0.77 vs 1.47) and continued to fall during open label (week 16: 0.68 vs 0.87), suggesting patients experienced a continued improvement in symptoms. Division of Diabetes, Endocrinology and Gastroenterology, The University of Manchester, Manchester, UK

Enterosgel Sachets, 10 x 15g Sachets - VictoriaHealth Enterosgel Sachets, 10 x 15g Sachets - VictoriaHealth

Virtual trial capability empowers patients; it allows any patient anywhere in the country to access the trial. It also means zero hospital visits which makes participation safer and easier for all. Children 15+ and adults: take 15g to 22.5g (≈ 1 tablespoon or 1–1.5 sachet) diluted in 200 ml of water 3 times a day. Ethics approval The study obtained ethical approval from the North West—Lancaster Research Ethics Committee (16/NW/0818). Study was approved by the Health Research Authority (HRA), UK. Enterosgel is suitable for people with coeliac disease. Enterosgel does not treat the coeliac disease itself, but it can help relieve the symptoms of diarrhoea. Enterosgel also adsorbs harmful substances that can lead to the build-up of gases and can thereby help relieve bloating. Certainly helped with bloating but the jury is out on urgency. Early days so I remain positive. I have diverticular disease which is severely affecting my quality of life but I have to say that I do feel better since starting the treatment.A product that works! After nearly 9 weeks of misery with no suggestions of a cure from any of the GPs in my surgery I turned to the internet and found Enterosgel. What was tested: Enterosgel was compared to placebo. This study monitors the safety and effectiveness of the treatment. No serious bad reactions, which are life threatening or require the patient to go to hospital, were related to treatment with Enterosgel.

Enterosgel UK | London - Facebook Enterosgel UK | London - Facebook

The next most common side effects were bloating reported by 3% of patients in the Enterosgel group and 1% of placebo patients. This product seems to be working for my post-infective IBS-C, despite the indications for its use in IBS-D. Pain and bloating improved as well as a return to normal bowel function. Had tried all allopathic treatments over the past seven years, including other alternative ones, to no avail, until now.Very grateful to the director of research for her very useful advice and support. A recent study published in the leading international journal GUT showed that ENTEROSGEL significantly improves diarrhoea, pain, bloating and urgency in people with IBS diarrhoea and increases overall quality of life. The results from this study apply to people aged 16 and above with the diarrhoea form of irritable bowel syndrome. However, this summary only shows the results from this one study. Other studies may find different results. Patients should not change their treatment based on the results of this study without first talking to their doctor or healthcare professional. Irritable Bowel Syndrome (IBS) is a common condition causing around 1 in 10 people to seek help from their GP at some point in their lives. It is a combination of abdominal discomfort or pain and altered bowel habits. IBS is classified as IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), or mixed IBS (IBS-M).

Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults Enterosgel is a versatile product, which can be used for a wide range of health problems, from IBS and food poisoning to skin complaints and hayfever. I’ve certainly got a tube in my first aid cupboard ready for use when needed. Enterosgel was developed in 1980’s and has been available as an over-the-counter treatment since 1996 in Europe. Since that time millions of people have used Enterosgel worldwide. There is a lot of scientific evidence to support Enterosgel, there have been lab-based studies to show how it works by binding and removing harmful substances from the gut that can cause diarrhoea and other symptoms, in both short-term diarrhoea (acute) and also in people with IBS with diarrhoea (IBS-D). Many clinical studies in both adults and children have shown that it is a safe and effective treatment. Two of these studies have been completed in the UK. The first was a randomised controlled trial investigating Enterosgel® for the treatment of acute diarrhoea in adults recruited from GP surgeries. This showed that Enterosgel significantly reduced the duration of diarrhoea in patients that either had a gastrointestinal infection or other causes for their short-term diarrhoea. The second was a large UK trial of 440 patients and investigated the efficacy and safety of Enterosgel in the treatment of patients with IBS-D. The results are just being published and show that Enterosgel is safe and effective treatment for the main IBS-D symptoms of; diarrhoea, abdominal pain, bloating, and urgency. After all trial patients got to take Enterosgel during the open label phase, 76% of them said that it gave then adequate relief of their IBS symptoms.